Charles Schwab Investment Management Inc. Purchases 52,498 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Charles Schwab Investment Management Inc. increased its position in shares of Replimune Group, Inc. (NASDAQ:REPL) by 12.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 484,797 shares of the company’s stock after purchasing an additional 52,498 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Replimune Group were worth $5,313,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Millennium Management LLC increased its holdings in Replimune Group by 575.1% in the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after acquiring an additional 2,656,173 shares during the last quarter. TD Asset Management Inc grew its stake in shares of Replimune Group by 4.6% in the 2nd quarter. TD Asset Management Inc now owns 249,940 shares of the company’s stock worth $2,249,000 after buying an additional 11,094 shares in the last quarter. Acadian Asset Management LLC grew its stake in shares of Replimune Group by 63.2% in the 2nd quarter. Acadian Asset Management LLC now owns 185,516 shares of the company’s stock worth $1,668,000 after buying an additional 71,867 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Replimune Group by 10.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 180,226 shares of the company’s stock worth $1,622,000 after buying an additional 17,471 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Replimune Group by 25.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 128,208 shares of the company’s stock worth $1,405,000 after buying an additional 25,939 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the transaction, the insider now directly owns 109,885 shares of the company’s stock, valued at $1,184,560.30. The trade was a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 8.80% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

REPL has been the subject of a number of recent research reports. HC Wainwright reissued a “buy” rating and issued a $17.00 price objective on shares of Replimune Group in a research note on Friday, November 22nd. Roth Mkm started coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective for the company. BMO Capital Markets lifted their price target on shares of Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a research note on Friday, November 22nd. Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Finally, Jefferies Financial Group lifted their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $17.29.

Replimune Group Stock Performance

Shares of NASDAQ REPL opened at $12.22 on Friday. The company’s fifty day moving average price is $12.17 and its 200 day moving average price is $10.40. Replimune Group, Inc. has a 1 year low of $4.92 and a 1 year high of $17.00. The company has a market capitalization of $836.06 million, a PE ratio of -4.01 and a beta of 1.26. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. On average, research analysts predict that Replimune Group, Inc. will post -2.91 earnings per share for the current year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.